2026 Q1 -tulosraportti
Vain PDF
21 päivää sitten
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 3 950 | - | - | ||
| 10 000 | - | - | ||
| 830 | - | - | ||
| 5 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 13.2. | ||
2025 Q3 -tulosraportti 14.11.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·13.5.Let's hope the drug becomes a success - and comes quickly to market - if only for the sake of the patients! The life science investment company KD Ventures' portfolio company Umecrine Cognition presents new data showing that over half of patients with primary biliary cholangitis suffer from severe fatigue and cognitive symptoms, which points to a clear need for new treatments. The analysis, based on nearly 2,000 patients, shows that these symptoms are perceived as more burdensome than itching, which challenges previous assumptions about the disease profile. The results will be presented at EASL 2026 in Barcelona. Umecrine is developing the drug candidate golexanolon, which targets neurological symptoms of the disease and is being evaluated in an ongoing phase 1b/2a study.
·12.5.There is a general meeting at KDV today. It will be interesting to see if there's any news about the portfolio.- ·11.5.today at 08:03 ∙ Finwire: The investment company KD Ventures is trading at an extreme NAV discount and is positioned for a possible share price recovery, according to Redeye, which initiates coverage with a fair value of 1 krona per share in the base scenario. The analysis firm points out that the biotech company's two largest holdings, Umecrine and Dilafor, account for approximately 80 percent of the net asset value of about 1.1 billion kronor, while the market capitalization amounts to about 170 million kronor. Redeye particularly highlights Umecrine's phase IIa results in the second half of the year as the most important catalyst of the year. A positive outcome could, according to the analysis firm, pave the way for a larger exit and a significant revaluation of the share. The valuation is set in the range of 0.4-1.7 kronor per share, where 0.4 is bear, 1.0 is base and 1.7 is bul The analysis firm points out that the biotech company's two largest holdings, Umecrine and Dilafor, account for approximately 80 percent of the net asset value of about 1.1 billion kronor, while the market capitalization amounts to about 170 million kronor.
- ·31.3.How large is the upcoming write-down of Forendo? As I read the financial statements, it concerns a write-down 18 mio. Corresponding to just under 2 % of the company's total value. Does anyone disagree with this? Not a huge problem, I think. And almost theoretical, when the total value of the company's entire portfolio in relation to the share price is 0, and the price only roughly corresponds to the cash balance.
- ·12.3. · MuokattuIncredible – but true. At a price of 0.23 SEK and a cash balance of an estimated minimum of 150 million SEK after the issue, one currently gets all underlying shares for free. Is there any other company with a similar offer? Normally, one would carry out a solvent liquidation of a company like this, find a buyer for the underlying shares and distribute the surplus to the shareholders, if the price cannot be driven up above the cash balance. However, that is not a scenario I desire. I prefer to wait patiently for the values to materialize – and buy up further in the meantime.·12.3.And don't forget the billion Swedish kronor they have in tax loss carryforward. For a buyer who can utilize it, it's worth up to 200 mill. It is booked at 0.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
21 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·13.5.Let's hope the drug becomes a success - and comes quickly to market - if only for the sake of the patients! The life science investment company KD Ventures' portfolio company Umecrine Cognition presents new data showing that over half of patients with primary biliary cholangitis suffer from severe fatigue and cognitive symptoms, which points to a clear need for new treatments. The analysis, based on nearly 2,000 patients, shows that these symptoms are perceived as more burdensome than itching, which challenges previous assumptions about the disease profile. The results will be presented at EASL 2026 in Barcelona. Umecrine is developing the drug candidate golexanolon, which targets neurological symptoms of the disease and is being evaluated in an ongoing phase 1b/2a study.
- ·12.5.There is a general meeting at KDV today. It will be interesting to see if there's any news about the portfolio.
- ·11.5.today at 08:03 ∙ Finwire: The investment company KD Ventures is trading at an extreme NAV discount and is positioned for a possible share price recovery, according to Redeye, which initiates coverage with a fair value of 1 krona per share in the base scenario. The analysis firm points out that the biotech company's two largest holdings, Umecrine and Dilafor, account for approximately 80 percent of the net asset value of about 1.1 billion kronor, while the market capitalization amounts to about 170 million kronor. Redeye particularly highlights Umecrine's phase IIa results in the second half of the year as the most important catalyst of the year. A positive outcome could, according to the analysis firm, pave the way for a larger exit and a significant revaluation of the share. The valuation is set in the range of 0.4-1.7 kronor per share, where 0.4 is bear, 1.0 is base and 1.7 is bul The analysis firm points out that the biotech company's two largest holdings, Umecrine and Dilafor, account for approximately 80 percent of the net asset value of about 1.1 billion kronor, while the market capitalization amounts to about 170 million kronor.
- ·31.3.How large is the upcoming write-down of Forendo? As I read the financial statements, it concerns a write-down 18 mio. Corresponding to just under 2 % of the company's total value. Does anyone disagree with this? Not a huge problem, I think. And almost theoretical, when the total value of the company's entire portfolio in relation to the share price is 0, and the price only roughly corresponds to the cash balance.
- ·12.3. · MuokattuIncredible – but true. At a price of 0.23 SEK and a cash balance of an estimated minimum of 150 million SEK after the issue, one currently gets all underlying shares for free. Is there any other company with a similar offer? Normally, one would carry out a solvent liquidation of a company like this, find a buyer for the underlying shares and distribute the surplus to the shareholders, if the price cannot be driven up above the cash balance. However, that is not a scenario I desire. I prefer to wait patiently for the values to materialize – and buy up further in the meantime.·12.3.And don't forget the billion Swedish kronor they have in tax loss carryforward. For a buyer who can utilize it, it's worth up to 200 mill. It is booked at 0.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 3 950 | - | - | ||
| 10 000 | - | - | ||
| 830 | - | - | ||
| 5 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 13.2. | ||
2025 Q3 -tulosraportti 14.11.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
2026 Q1 -tulosraportti
Vain PDF
21 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 13.2. | ||
2025 Q3 -tulosraportti 14.11.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·13.5.Let's hope the drug becomes a success - and comes quickly to market - if only for the sake of the patients! The life science investment company KD Ventures' portfolio company Umecrine Cognition presents new data showing that over half of patients with primary biliary cholangitis suffer from severe fatigue and cognitive symptoms, which points to a clear need for new treatments. The analysis, based on nearly 2,000 patients, shows that these symptoms are perceived as more burdensome than itching, which challenges previous assumptions about the disease profile. The results will be presented at EASL 2026 in Barcelona. Umecrine is developing the drug candidate golexanolon, which targets neurological symptoms of the disease and is being evaluated in an ongoing phase 1b/2a study.
- ·12.5.There is a general meeting at KDV today. It will be interesting to see if there's any news about the portfolio.
- ·11.5.today at 08:03 ∙ Finwire: The investment company KD Ventures is trading at an extreme NAV discount and is positioned for a possible share price recovery, according to Redeye, which initiates coverage with a fair value of 1 krona per share in the base scenario. The analysis firm points out that the biotech company's two largest holdings, Umecrine and Dilafor, account for approximately 80 percent of the net asset value of about 1.1 billion kronor, while the market capitalization amounts to about 170 million kronor. Redeye particularly highlights Umecrine's phase IIa results in the second half of the year as the most important catalyst of the year. A positive outcome could, according to the analysis firm, pave the way for a larger exit and a significant revaluation of the share. The valuation is set in the range of 0.4-1.7 kronor per share, where 0.4 is bear, 1.0 is base and 1.7 is bul The analysis firm points out that the biotech company's two largest holdings, Umecrine and Dilafor, account for approximately 80 percent of the net asset value of about 1.1 billion kronor, while the market capitalization amounts to about 170 million kronor.
- ·31.3.How large is the upcoming write-down of Forendo? As I read the financial statements, it concerns a write-down 18 mio. Corresponding to just under 2 % of the company's total value. Does anyone disagree with this? Not a huge problem, I think. And almost theoretical, when the total value of the company's entire portfolio in relation to the share price is 0, and the price only roughly corresponds to the cash balance.
- ·12.3. · MuokattuIncredible – but true. At a price of 0.23 SEK and a cash balance of an estimated minimum of 150 million SEK after the issue, one currently gets all underlying shares for free. Is there any other company with a similar offer? Normally, one would carry out a solvent liquidation of a company like this, find a buyer for the underlying shares and distribute the surplus to the shareholders, if the price cannot be driven up above the cash balance. However, that is not a scenario I desire. I prefer to wait patiently for the values to materialize – and buy up further in the meantime.·12.3.And don't forget the billion Swedish kronor they have in tax loss carryforward. For a buyer who can utilize it, it's worth up to 200 mill. It is booked at 0.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 3 950 | - | - | ||
| 10 000 | - | - | ||
| 830 | - | - | ||
| 5 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt